Cancer Diagnostics – Products

This whitepaper demonstrates how common methylation detection methods can be combined with Droplet Digital PCR (ddPCR) to enhance the cfDNA analysis for clinical and research applications.

This case study presents a scalable, automation-friendly workflow for active deparaffinization, extraction and purification of nucleic acids from FFPE samples that can transform cancer diagnostics as demand grows.

New Celselect slides™ design increases efficiency of circulating tumor cell capture from liquid biopsy samples for enumeration and downstream applications.

This app note highlights a robust targeted RNA enrichment workflow that integrates automation to expedite library preparation and data analysis.

Optimer binders will be developed for use in a cervical cancer blood test. Agreement for up to £465,000 signed for Optimer development.

Distinguish 5mC & 5hmC together with all 4 canonical bases to measure multiple modes of biology from a 5ng cfDNA sample in a single experiment. Identify new multimodal biomarkers to gain transformative insight into current & future states of disease.

Collaboration aims to provide researchers cutting-edge tools to enable transformational monitoring of key biomarkers in solid tissue transplants.

Collaboration aims to grow clinical evidence supporting the use of bio-Rad’s ddPCR™ technology for molecular residual disease monitoring of patients across a range of solid tumor types.

Highly sensitive and multiplexed assay for the detection, discrimination, and quantification of key mutations in ESR1 gene for breast cancer, developed for bio-Rad’s QX600™ droplet digital™ PCR system.

Antibodies validated for use with bio-Rad’s Celselect slides™ enumeration stain kits to enable immunostaining of captured circulating tumor cells in liquid biopsy samples.